Sex and cardiovascular disease status differences in attitudes and willingness to participate in clinical research studies/clinical trials

Trials
Thomas S GrucaGary E Rosenthal

Abstract

While women are under-represented in research on cardiovascular disease (CVD), little is known about the attitudes of men and women with CVD regarding participation in clinical research studies/clinical trials. Patients with CVD (and/or risk factors) and patients with other chronic conditions from Iowa were recruited from a commercial panel. An on-line survey assessed willingness to participate (WTP) and other attitudes towards aspects of clinical research studies. Based on 504 respondents, there were no differences in WTP in patients with CVD compared to patients with other chronic diseases. Across all respondents, men had 14% lower WTP (relative risk (RR) for men, 0.86, 95% CI, 0.72-1.02). Among patients with CVD, there was no significant difference in WTP between women (RR for women = 1) and men (RR for men, 0.96, 95% CI, 0.82-1.14). There were no significant differences based on sex or CVD status for attitudes on randomization, blinding, side effects, conflict of interest, experimental treatments or willingness to talk to one's physician. Women had more favorable attitudes about participants being treated like "guinea pigs" (RR for men, 0.84, 95% CI, 0.73-0.98) and clinical trials being associated with terminally ill patien...Continue Reading

References

Aug 1, 1997·Controlled Clinical Trials·L C LovatoJ L Probstfield
Aug 10, 2001·JAMA : the Journal of the American Medical Association·P Y LeeE D Peterson
Jan 15, 2002·Journal of the American College of Cardiology·Steven P SchulmanGary Gerstenblith
Mar 22, 2002·Journal of Internal Medicine·S M MadsenP Riis
Jul 19, 2002·JAMA : the Journal of the American Medical Association·Jacques E RossouwUNKNOWN Writing Group for the Women's Health Initiative Investigators
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert L ComisEllen Stoval
Dec 19, 2003·Journal of Clinical Epidemiology·Ffion Lloyd-WilliamsDerek Connelly
Mar 23, 2004·American Journal of Epidemiology·Guangyong Zou
Mar 9, 2005·The New England Journal of Medicine·Paul M RidkerJulie E Buring
Nov 17, 2005·Journal of the National Cancer Institute. Monographs·Tung T NguyenThoa Nguyen
Apr 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy E AvisEdgardo Rivera
Jan 4, 2007·Journal of Women's Health·Stacie E GellerMolly Carnes
Aug 24, 2007·Clinical Trials : Journal of the Society for Clinical Trials·Mimi Sen BiswasJeremy Sugarman
Jan 22, 2010·The Cochrane Database of Systematic Reviews·Shaun TreweekRitu Jones
Feb 12, 2010·Circulation. Cardiovascular Quality and Outcomes·Lori MoscaKaren J Robb
Feb 18, 2010·Circulation. Cardiovascular Quality and Outcomes·Chiara MelloniL Kristin Newby
Apr 15, 2010·Journal of Health Communication·Katherine A McComasHildy Dillon
Apr 16, 2010·The Cochrane Database of Systematic Reviews·Shaun TreweekElizabeth Mitchell
Feb 16, 2013·Journal of the American College of Cardiology·Seth S MartinTracy Y Wang
Aug 30, 2013·Journal of Health Services Research & Policy·Sharon McCannVikki Entwistle
Dec 3, 2013·Journal of Medical Internet Research·Benjamin M CraigBryce B Reeve

❮ Previous
Next ❯

Software Mentioned

Qualtrics

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.